DURECT

DRRX NASDAQ
0.7266
+0.0527
+7.82%
盘后: 0.7299 +0.0033 +0.45% 17:31 07/19 EDT
开盘
0.6900
昨收
0.6739
最高
0.7300
最低
0.6900
成交量
36.30万
成交均量(3M)
95.58万
52周最高
1.660
52周最低
0.4600
换手率
0.19%
市值
1.39亿
分时
5日
1月
3月
1年
5年

相关股票

微牛行情栏目提供DURECT DRRX股票价格,DURECT股票实时行情,公司简介,财报信息,股本结构等,掌握美港股行情走势,开盘价,收盘价,总市值,换手率,市盈率,收益率等数据,及时把握美股港股投资机会。

公司介绍

Durect Corporation is a biopharmaceutical company with research and development programs. The Company's products candidates include DUR-928, oral for metabolic/lipid disorders, and DUR-928, injectable for acute organ injuries. Its other product candidates include POSIMIR (controlled release injection of bupivacaine), REMOXY (oral controlled release oxycodone), ORADUR-ADHD, ELADUR (controlled release injection of bupivicane), Relday (risperidone), ORADUR-based opioid (hydromorphone) and SABER-based ophthalmic. The Company's ALZET product line consists of miniature, implantable osmotic pumps and accessories used for experimental research in mice, rats and other laboratory animals. The Company also manufactures and sells osmotic pumps used in laboratory research and design; and develops and manufactures a range of standard and custom biodegradable polymers and excipients for pharmaceutical and medical device clients for use as raw materials in their products.
展开 >

最近浏览

名称
价格
涨跌幅